{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:15:10Z","timestamp":1788383710655,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012173","name":"China-Japan Friendship Hospital","doi-asserted-by":"publisher","award":["ZRJY2023-GG02"],"award-info":[{"award-number":["ZRJY2023-GG02"]}],"id":[{"id":"10.13039\/501100012173","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.semarthrit.2024.152536","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T15:23:17Z","timestamp":1723303397000},"page":"152536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clinical characteristics of idiopathic inflammatory myopathies patients with anti-PM\/Scl antibodies"],"prefix":"10.1016","volume":"68","author":[{"given":"Longyang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3674-9307","authenticated-orcid":false,"given":"Yongpeng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2024.152536_bib0001","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0002","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0003","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0004","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0005","article-title":"Interstitial lung disease is a major characteristic of patients who test positive for anti-PM\/Scl antibody","volume":"8","author":"Ge","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0006","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1093\/rheumatology\/keac090","article-title":"Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"61","author":"Gui","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0007","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0008","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0009","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0010","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0011","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0012","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0013","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscular Disorders"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0017","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1002\/art.23963","article-title":"Reliability and validity of the myositis disease activity assessment tool","volume":"58","author":"Sultan","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0018","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/rheumatology\/keab305","article-title":"Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study","volume":"61","author":"Wu","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2009.09484.x","article-title":"Long-term outcome of patients with polymyositis\/dermatomyositis and anti-PM-Scl antibody","volume":"162","author":"Marie","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0022","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11926-011-0176-8","article-title":"Antisynthetase syndrome","volume":"13","author":"Katzap","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0023","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jdv.14759","article-title":"Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients","volume":"32","author":"Best","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0024","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/rheumatology\/keab177","article-title":"Palmar erythema and palmar papules as predictors for dermatomyositis-related acute\/subacute interstitial lung disease: a retrospective study","volume":"61","author":"Lu","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0025","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1093\/rheumatology\/keaa618","article-title":"Clinical features, treatments and outcomes of calcinosis in adult patients with dermatomyositis: a single cohort study","volume":"60","author":"Jiang","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1237209","article-title":"Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study","volume":"14","author":"Ji","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102355","article-title":"Interstitial lung disease associated with anti-PM-Scl antibody: a single center experience","volume":"18","author":"Ussavarungsi","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0028","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3899\/jrheum.090652","article-title":"Interstitial lung disease associated with anti-PM\/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?","volume":"37","author":"Lega","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0029","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotypes","volume":"5","author":"Ghirardello","year":"2014","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays","volume":"18","author":"Damoiseaux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10081725","article-title":"Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies","volume":"10","author":"Okiyama","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0032","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.24993","article-title":"Long-term outcomes and prognosis factors in patients with idiopathic inflammatory myopathies based on myositis-specific autoantibodies: a single cohort study","volume":"75","author":"Jiang","year":"2023","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0033","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0034","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.845988","article-title":"Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome","volume":"13","author":"Zuo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0036","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/joim.13607","article-title":"Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis","volume":"293","author":"Jin","year":"2023","journal-title":"J Intern Med"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0037","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1136\/annrheumdis-2019-216372","article-title":"Association of anti-Ro52 autoantibodies with interstitial lung disease in connective tissue diseases","volume":"80","author":"Wu","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0038","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0039","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152536_bib0040","doi-asserted-by":"crossref","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis","volume":"68","author":"Cruellas","year":"2013","journal-title":"Clinics"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:15:03Z","timestamp":1726618503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224001768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":39,"alternative-id":["S0049017224001768"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152536","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics of idiopathic inflammatory myopathies patients with anti-PM\/Scl antibodies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152536"}}